Key points at a glance
- Local steroid injections can meaningfully raise blood glucose, especially over the first 24–72 hours, with peaks sometimes delayed several days; excursions are larger in those with poorer baseline control.
- Systemic effects do occur after “local” injections: measurable HPA-axis suppression commonly lasts 2–4 weeks (longer with higher doses/frequency), and short-term suppression of immune cell counts and cytokines is documented.
- Musculoskeletal safety signals include cartilage volume loss with repeated intra-articular triamcinolone for knee OA, elevated infection risk around arthroplasty when injections are given close to surgery, and tendon rupture (rare but real).
- Platelet-rich plasma (PRP) is autologous (no steroid, no exogenous drug) and is increasingly supported by randomised trials and meta-analyses across common indications (knee OA, rotator cuff disease, lateral epicondylitis), with fewer systemic risks than corticosteroid injections.
Why diabetes changes the calculus for steroid injections
Corticosteroids remain useful anti-inflammatories, but their glycaemic effect is clinically significant even when given into a joint or tendon sheath. Continuous and capillary glucose studies consistently show post-injection hyperglycaemia in people with diabetes; rises are typically observed within 1–3 days, can be substantial, and are greater when HbA1c is higher at baseline.
Beyond glucose, “local” steroids can behave systemically. HPA-axis suppression after intra-articular/epidural steroids is common for 2–4 weeks (sometimes up to 8 weeks depending on dose and frequency). Clinicians should assume low morning cortisol values are possible for several weeks post-injection. Experimental and clinical data also demonstrate transient immunosuppression (reductions in immune cell numbers up to 48 h, cytokine changes beyond 96 h), which is biologically consistent with the infection signals discussed below.
Practical monitoring advice for patients with diabetes
- Plan for intensified glucose monitoring for at least 3–5 days after a steroid injection; earlier if symptoms suggest hyperglycaemia. Adjust insulin/sulphonylurea per your diabetes plan. (JBDS guidance provides pragmatic algorithms for steroid-induced hyperglycaemia management.)
- Schedule injections away from intercurrent illness and away from planned surgery, given immunosuppressive and infection-risk considerations (see below).
Other material risks of corticosteroid injections in musculoskeletal care
- Cartilage health (knee OA): In a two-year RCT (triamcinolone every 12 weeks vs saline), steroids increased cartilage volume loss with no pain benefit over placebo—raising legitimate disease-modification concerns with repeated dosing.
- Peri-operative infection risk: Meta-analyses and large database studies indicate higher periprosthetic joint infection (PJI) rates when intra-articular steroid injections are given within ≈3 months prior to joint arthroplasty (shoulder, hip; knee data mixed but trending cautious). Many authors recommend a minimum 3-month “wash-out”.
- Tendon integrity: Case series and reviews continue to report tendon rupture after corticosteroid injections, particularly with repeat dosing or intratendinous placement. Risk is low but non-trivial.
- Systemic adverse effects: Contemporary radiology and endocrine reviews catalogue adrenal suppression, hyperglycaemia, hypertension, osteoporosis, skin changes, facial flushing and more—even after “local” delivery. These effects are dose- and frequency-dependent.
My clinical assessment: steroids can be appropriate for acute flares or diagnostic value, but the risk–benefit ratio degrades with repetition, particularly in people with diabetes or those contemplating surgery.
Where PRP fits—and why it avoids steroid liabilities
PRP is prepared from the patient’s own blood and delivers a concentrated milieu of platelets and growth factors to injured tissue; it does not contain corticosteroid and therefore does not carry steroid-specific systemic risks(hyperglycaemia, HPA suppression, steroid-related chondrotoxicity). Systematic reviews across orthopaedic indications now show clinically relevant advantages for PRP over alternatives:
- Knee osteoarthritis: Multiple meta-analyses (2024–2025) report superior pain and function outcomes vs hyaluronic acid and better results than corticosteroid/placebo over short- to mid-term follow-up; repeated injections do not demonstrate cartilage loss.
- Rotator cuff tendinopathy: Recent pooled analyses show significant improvements in pain and function with PRP versus controls.
- Lateral epicondylitis: High-level evidence indicates steroids may help short-term, but PRP outperforms by 6–12 months on pain and function—more aligned with tendon biology.
Safety profile
Across orthopaedic trials, major adverse events are rare; most reports note only transient post-injection ache or swelling. No steroid-type metabolic or endocrine effects are expected. (As with any injection, infection is possible but uncommon when proper technique is used.) Broader safety reviews remind us that rare, indication-specific complications can occur (e.g., ocular interventions), underscoring the need for proper case selection and sterile technique.
My clinical assessment: For tendinopathies and degenerative joint problems, PRP aligns better with the goals of biologic repair and durable improvement, without exposing patients—especially those with diabetes—to steroid-related systemic risks.
How I counsel patients with diabetes who are weighing injections
- Clarify goals and time-horizon. If the aim is a brief anti-inflammatory window (e.g., to facilitate physiotherapy), a single, carefully timed steroid may be considered—with glucose monitoring and surgical date planning. For durable pain and function gains, PRP is often the better bet biologically and clinically.
- Discuss glycaemic plans up front if any steroid is used. Increase glucose checks for 3–5 days and have an adjustment protocol ready with the diabetes team.
- Avoid injections close to arthroplasty. I advise ≥3 months between a steroid injection and elective joint replacement where possible.
- Be transparent about funding. In many systems, PRP is self-funded. In my view, for appropriate indications and patient profiles (notably people with diabetes), PRP should be considered a sound alternative to steroids even without insurance funding, because it avoids steroid liabilities and offers better medium-term outcomes in several conditions.
FAQ for patients (diabetes-focused)
- “Will a steroid shot spike my sugars?”Very likely, yes—usually for 1–3 days, sometimes longer, and more so if baseline HbA1c is high. Plan monitoring and medication adjustments.
- “Do joint or tendon steroid shots ‘affect the whole body’?”Yes, transiently. Expect HPA suppression for 2–4 weeks and short-term immunosuppression.
- “Is PRP safer for my diabetes?”Metabolically, yes. PRP has no steroid, so hyperglycaemia and HPA suppression are not expected; adverse events are typically local and transient.
Bottom line
Corticosteroid injections can still play a limited, targeted role, but in people with diabetes their systemic ripple effects—hyperglycaemia, HPA-axis suppression, and infection-related concerns around surgery—require caution, planning, and restriction of frequency. Where the clinical objective is sustained improvement in musculoskeletal pain and function, PRP represents a biologically coherent and increasingly evidence-supported alternative, with a favourable safety profile and no steroid-specific metabolic costs. Even when unfunded, the long-term benefit-to-risk ratio for PRP is often superior—and that is ultimately the metric that should guide care.
References
- Safran O, et al. Effect of shoulder corticosteroid injection on glycaemia in T2DM. 2022.
- Choudhry MN, et al. Blood glucose after intra-articular steroid injection. 2016.
- Aleem AW, et al. Glucose changes in diabetic patients following corticosteroid injection. 2017.
- Kreulen RT, et al. HPA suppression after intra-articular steroids. 2023.
- Beuschlein F, et al. Diagnosis & therapy of glucocorticoid-induced adrenal insufficiency. 2024.
- Regan P, et al. Systemic immunosuppressive effects after peripheral steroid injections. 2021.
- McAlindon TE, et al. Triamcinolone vs saline in knee OA: cartilage loss, no pain benefit. JAMA 2017.
- Kim YM, et al. Pre-TKA steroid injection and PJI risk (meta-analysis). 2023.
- Muffly BT, et al. Prior steroid within 3 mo and deep infection after arthroplasty (meta-analysis). 2024.
- Albanese J, et al. THA infection risk after prior steroid injection. 2023.
- Inomori Y, et al.; Lu H, et al. Tendon rupture after steroid injection. 2023; 2016.
- Pelluri R, et al. PRP vs placebo/CS in knee OA (meta-analysis). 2024.
- Oeding JF, et al. PRP vs alternative injections in knee OA (meta-analysis). 2024.
- Bahadir B, et al.; Roy M, et al. PRP for rotator cuff: efficacy meta-analyses. 2024; 2025.
- Xu Y, et al.; Maroun R, et al. PRP vs CS for lateral epicondylitis. 2024; 2025.
- Cureus/orthopaedic SRs and institutional overviews on PRP safety. 2024.